| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3943578 | Gynecologic Oncology | 2007 | 5 Pages |
Abstract
Our recommended dose for a phase II trial of concurrent chemoradiation with weekly nedaplatin is 35Â mg/m2. The formula can predict unbound concentration of nedaplatin based on area under the curve within 25% error.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Kohsuke Yoshinaga, Hitoshi Niikura, Yoshihiro Ogawa, Kenji Nemoto, Satoru Nagase, Tadao Takano, Kiyoshi Ito, Nobuo Yaegashi,